Actinium Pharmaceuticals, Inc. ATNM
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
Actinium Pharmaceuticals, Inc. (ATNM) is a healthcare company listed in the US with a market value of about $52M. In the twelve months to June 30, 2026 it had revenue of $35M and net income of $11M, a net margin of 32.2%.
Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is value (2/5); the weakest is track record (0/5).
Key numbers: a P/E of 4.6, a 5-year average ROIC of -109%.
About Actinium Pharmaceuticals
Actinium Pharmaceuticals is listed in the US and classified in biotechnology: pharmaceutical preparations. Revenue went from $1M in 2021 to $90000 in 2025, a decline of about 47.0% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 29% over three years (dilution for shareholders). It spends 23471% of revenue on research and development.
Score: 1.0 / 5
Checks passed
- P/E below 25
- P/E below the industry median
- Profit margin improving
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
Checks not passed
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year revenue growth above 8% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $35M | $90000 | — | $81000 | $1M | $1M | — | — | — | — | — |
| Net income | $11M | -$34M | -$38M | -$49M | -$33M | -$25M | -$22M | -$22M | -$24M | -$27M | -$24M |
| Free cash flow | — | -$25M | -$33M | -$47M | $8M | -$21M | -$22M | -$22M | -$21M | -$22M | -$21M |
| EPS (diluted) | $0.36 | $-1.09 | $-1.27 | $-1.83 | $-1.37 | $-1.20 | $-1.83 | $-4.40 | $-6.60 | $-12.00 | $-15.00 |
| Net margin | 32.2% | -37652.2% | — | -60269.1% | -3205.5% | -2165.6% | — | — | — | — | — |
| ROIC | — | -300.9% | -97.0% | -88.4% | -34.0% | -24.9% | -26.8% | -241.8% | -207.7% | -155.5% | -117.8% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
What is Actinium Pharmaceuticals’s P/E ratio?
About 4.6, based on the last twelve months of diluted earnings per share.
Does Actinium Pharmaceuticals pay a dividend?
Not currently.
Is Actinium Pharmaceuticals a good stock to buy?
We do not give buy or sell advice. Actinium Pharmaceuticals scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.